|
SLC19A2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.14120000005435E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.28100000051923E-07 |
| Normal-vs-Stage2 |
1.93089999545037E-08 |
| Normal-vs-Stage3 |
2.08340000029672E-07 |
| Normal-vs-Stage4 |
4.98110000024532E-07 |
| Stage1-vs-Stage2 |
1.145190E-01 |
| Stage1-vs-Stage3 |
8.877800E-01 |
| Stage1-vs-Stage4 |
5.960800E-01 |
| Stage2-vs-Stage3 |
1.202620E-01 |
| Stage2-vs-Stage4 |
9.015800E-02 |
| Stage3-vs-Stage4 |
7.478600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.08139999960488E-07 |
| Normal-vs-AfricanAmerican |
4.716699999463E-07 |
| Normal-vs-Asian |
2.59889999520979E-08 |
| Caucasian-vs-AfricanAmerican |
8.670800E-01 |
| Caucasian-vs-Asian |
6.690200E-02 |
| AfricanAmerican-vs-Asian |
1.740840E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.64699999971596E-07 |
| Normal-vs-Female |
1.15189999982945E-07 |
| Male-vs-Female |
9.514600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.78650000021352E-07 |
| Normal-vs-Age(41-60Yrs) |
3.77329999468046E-08 |
| Normal-vs-Age(61-80Yrs) |
1.45380000038386E-07 |
| Normal-vs-Age(81-100Yrs) |
1.006400E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.577700E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.940000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.990400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.764800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.404200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.185000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.858500E-03 |
| Classical-VS-Follicular |
5.353600E-02 |
| Classical-VS-Other |
5.953600E-01 |
| Classical-VS-Normal |
3.31620000015853E-07 |
| Tall-VS-Follicular |
3.769600E-01 |
| Tall-VS-Other |
1.425580E-02 |
| Tall-VS-Normal |
1.92619999950239E-08 |
| Follicular-VS-Other |
1.779840E-01 |
| Follicular-VS-Normal |
5.49530000393261E-08 |
| Other-VS-Normal |
2.41359999999524E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.99650000368246E-08 |
| Normal-vs-N1 |
7.51269999987869E-07 |
| N0-vs-N1 |
1.049590E-01 |
|
|
